ID
9962
Description
Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel(TM)) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
Keywords
Versions (5)
- 3/5/15 3/5/15 -
- 3/9/15 3/9/15 -
- 4/24/15 4/24/15 -
- 12/15/15 12/15/15 -
- 2/11/16 2/11/16 -
Uploaded on
March 9, 2015
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0 Legacy
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
End of Study AMLSG 21-13 NCT02013648 Akute myeloische Leukämie (AML)
End of Study AMLSG 21-13 NCT02013648 Akute myeloische Leukämie (AML)
Description
Signature
Similar models
End of Study AMLSG 21-13 NCT02013648 Akute myeloische Leukämie (AML)
C0205447 (UMLS CUI-2)
C1533734 (UMLS CUI-3)
C0205448 (UMLS CUI-2)
C1533734 (UMLS CUI-3)
C0205447 (UMLS CUI-2)
C1533734 (UMLS CUI-3)
C0205448 (UMLS CUI-2)
C1533734 (UMLS CUI-3)
C0205449 (UMLS CUI-2)
C1533734 (UMLS CUI-3)
C0205450 (UMLS CUI-2)
C1533734 (UMLS CUI-3)
C1533734 (UMLS CUI-2)